Bleeding risk ends aspirin-clopidogrel trial

10/10/2011 | TheHeart.org (Montreal) (free registration)

The National Institute of Neurological Disorders and Stroke has halted the study of an aspirin-clopidogrel combination in the Secondary Prevention of Small Subcortical Strokes trial. Mortality rates and bleeding risk were higher for that combination, and an analysis showed little chance of benefit.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY